Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-13
2007-03-13
Wilson, James O. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S359000, C514S396000
Reexamination Certificate
active
10289924
ABSTRACT:
Non-peptide somatostatin receptor ligands with conformationally restricted side chains exhibiting high binding affinity toward somatostatin receptors are provided. The compounds exhibit a high selectivity and act as agonists at human subtype 2 somatostatin receptors. The compounds are long acting for advantageous use as medicaments in peripheral diseases where somatostatinergic therapy is indicated. Furthermore, many of the compounds are lipophilic and are particularly useful for treating central nervous system and ophthalmic diseases where penetration of the blood brain and blood retinal barriers is required. It is a further object to describe the preferred stereoisomers of these somatostatin agonists and processes for their preparation. Further objects will become apparent from reading the following description.
REFERENCES:
patent: 5776894 (1998-07-01), Albert et al.
patent: 6025372 (2000-02-01), Yang et al.
patent: 6057338 (2000-05-01), Yang et al.
patent: 6063796 (2000-05-01), Yang et al.
patent: 6117880 (2000-09-01), Guo et al.
patent: 6225284 (2001-05-01), Albert et al.
patent: 6241965 (2001-06-01), Dean et al.
patent: 6262229 (2001-07-01), Coy et al.
patent: 6265375 (2001-07-01), Gilon et al.
patent: 6268342 (2001-07-01), Culler et al.
patent: 6294520 (2001-09-01), Naito
patent: 6316004 (2001-11-01), Lunin et al.
patent: 6316414 (2001-11-01), Burman et al.
patent: 6344358 (2002-02-01), Matsuoka et al.
patent: 6346601 (2002-02-01), Obiols et al.
patent: 6352982 (2002-03-01), Mabuchi et al.
patent: 6355613 (2002-03-01), Hornik et al.
patent: 6358491 (2002-03-01), Lister-James et al.
patent: 6387932 (2002-05-01), Zhou et al.
patent: 2001/0011072 (2001-08-01), Culler et al.
patent: 2001/0025097 (2001-09-01), Sheridan et al.
patent: 2002/0016298 (2002-02-01), Hay et al.
patent: 2002/0052315 (2002-05-01), Hornik et al.
patent: 0 615 630 (1985-12-01), None
patent: 642159 (1950-08-01), None
patent: 643089 (1950-09-01), None
patent: 652207 (1951-04-01), None
patent: 985966 (1965-03-01), None
patent: 2 227 488 (1990-08-01), None
patent: 2 351 733 (2001-01-01), None
patent: WO 98/44921 (1998-10-01), None
patent: WO 98/44922 (1998-10-01), None
patent: WO 98/45285 (1998-10-01), None
patent: WO 99/22735 (1999-05-01), None
patent: WO 00/61587 (2000-10-01), None
patent: WO 00/70347 (2000-11-01), None
patent: WO 00/75186 (2000-12-01), None
patent: WO 01/00676 (2001-01-01), None
patent: WO 01/07424 (2001-02-01), None
patent: WO 01/09090 (2001-02-01), None
patent: WO 01/85718 (2001-11-01), None
patent: WO 01/85718 (2001-11-01), None
patent: WO 02/09739 (2002-02-01), None
patent: WO 02/10140 (2002-02-01), None
patent: WO 02/10192 (2002-02-01), None
patent: WO 02/10215 (2002-02-01), None
patent: WO 02/26766 (2002-04-01), None
Fetter et al, Hydantoins, thiohydantoins, glycocyamidnes . . . Acta Chimica Academiae Scientaiarum Hungaricae (1973), 78(3), 325-33.
Albert, R., et al., “Direct Synthesis of [DOTA-Dphe1]-Octreotide and [DOTA-Dphe1,Tyr3]-Octreotide (SMT487): Two Conjugates for Systemic Delivery of Radiotherapeutical Nuclides to Somatostatin Receptor Positive Tumors in Man”,Bioorg. Med. Chem. Lett.(1998), 8:1207-1210; Elsevier Science Ltd.
Arnold, R., et al., “Somatostatin Analog Sandostatin and Inhibition of Tumor Growth in Patients with Metastatic Endocrine Gastroenteropancreatic Tumors”,World J. Surg.(1993), 17:511-519; Société Internationale de Chirurgie.
Bauer, W., et al., “A very potent and selective octapeptide analog of somatostatin with prolonged action”,Life Sciences(1982), 31:1133-40.
Guisti, et al., “Clinical results of long-term slow-release lanreotide treatment of acromegaly”,Euro. J. Clin. Investigation(1997), 27(4):277-84.
Kessler, et al., “Peptide Conformations. 28. Relayed Heteronuclear Correlation Spectroscopy and Conformational Analysis of Cyclic Hexapeptides Containing the Active Sequence of Somatostatin,”J. Am. Chem. Soc.(1983), 105:6944-6952.
Krenning, E.P., et al., “Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam Experience with more than 1000 patients”,Eur. J. Nuc. Med.(1993), 20(8):715-731; Springer-Verlag.
Liebow, et al., “Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase”,Proc. Natl. Acad. Sci.(1989), 86:2003-2007.
Pasternak, A., et al., “Potent, orally, bioavailable Somatostatin agonists: good absorption achieved by urea backbone cyclization”,Bioorg. Med. Chem. Lett.(1999), 9(3):491-496.
Rohrer, et al., “Rapid Identification of Subtype-Selective Agonists of the Somatostatin Receptor Through Combinational Chemistry”,Science(1998), 282:737-740.
Scicinski, J.J., et al., “The solid phase synthesis of a series of tri-substituted hydantoin ligands for the somatostatin SST5 receptor”,Bioorg. Med. Chem. Lett.(1998), 8(24):3609-14.
Yang, et al., “Potent and Selective Non-Peptide Human Somatostatin Receptor Subtype-2 (hSSTR-2) agonists”, Book of Abstracts, 216thACS National Meeting, Boston, MA, Aug. 23-27 (1998); MEDJ-194.
Yang, et al., “Spiro[1H-indene-1,4-piperidine] Derivatives As Potent and Selective Non-Peptide Human Somatostatin Receptor Subtype 2 (sst2) Agonists”,J. Med. Chem.(1998), 41(13):2175-2179.
Yang, et al., “Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2”,Proc. Natl. Acad. Sci. USA(1998), 95(18):10836-10841.
Yang, L. “Non-peptide Somatostatin Receptor Ligands”,Ann. Rep. Med. Chem.(Chapter 21) (1999), 34:209-218; Academic Press.
Yang, et al., “2,4-bis (aminomethyl) pyridine derived highly potent and selective human somatostatin receptor subtype-2 (hsst2) agonists”, Book of Abstracts, 217thACS National Meeting, Anaheim, CA, Mar. 21-25, 1999; MEDJ-141.
Yang, et al., “The Design and Synthesis of Non-Peptide Somatostatin Receptor Agonists”, Dept. New Millennium, Proc. Am. Pept. Symp., 16th(2000), Meeting date 1999:250-252.
Jurczyk Simona
Lockwood Mark A.
Natchus Michael G.
Shapiro Gideon
Saliwanchik Lloyd & Saliwanchik
Ward Paul V.
Wilson James O.
LandOfFree
Non-peptide somatostatin receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-peptide somatostatin receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-peptide somatostatin receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3782140